GlobeImmune (GBIM) Tacks on Another 30% on Little News

Steve Kanaval  |

GlobeImmune (GBIM) rallied another 30% today on 10 million shares at mid point of today's trading trading $2.65 today after opening the week at $1.19 more than a 100% higher.

As our writer pointed out in yesterdays article, " Globelimmune Inc. (GBIM) fights disease in a way that can only be described as inexplicable. The unusual method involves a heat-inactivated yeast containing Tarmogen, which if all goes well reduces target cells that also contain Tarmogen. Undoubtedly, the most interesting aspect of collaborations with Gilead (GILD) and Celgene (CELG) and for a company valued at $12m as of mid-June 2016, the potential profits of the partnerships are strong . "

Click here to read previous article

I express caution as often these riptide moves roll into secondary offerings where shares get a down draft. Also little news has come from the company itself which always leaves me with questions. We have reached out to the company and will report back.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
GBIM GlobeImmune Inc. 0.06 0.00 0.00 0

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     

Can the Media Solve the Partisan Conflict?

Andrew McCarthy, Contributing Editor, The National Review; Michael Zeldin, CNN Legal Analyst; Celeste Katz, Senior Political Reporter, Glamour; Silvia Davi, SVP, Contributing Editor, Equities.com; and Doug Simon, CEO, D S Simon Media discuss how the media’s role has shaped the landscape for communicators and what the media is trying to do to reduce discord in society.